Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Houede

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 4, 2019
[Immunotherapy in urology: Concept and results]G Pignot, N Houede
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 15, 2011
[Bone prevention in prostate cancer]T Bessede, N Houede, T Lebret
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 27, 2012
[Intradiverticular bladder tumours: review of the Cancer Committee of the French Association of Urology]Y Neuzillet, E Comperat, M Rouprêt, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 5, 2013
[Surgical treatment of metastatic urothelial carcinoma of the bladder: Review of the Cancer Committee of the French Association of Urology]Y Neuzillet, S Larré, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trialK Fizazi, G Gravis, A Flechon, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 19, 2016
[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]Y Neuzillet, P Colin, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 8, 2015
[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)]Y Neuzillet, F Dubosq, E Xylinas, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 7, 2010
[Recommendations Onco-Urology 2010: Urothelial tumors]C Pfister, M Roupret, H Wallerand, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]E Compérat, S Larré, Y Neuzillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)M Roupret, A Bertaut, G Pignot, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 4, 2019
[Immunotherapy in urology: Concept and results]G Pignot, N Houede
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 15, 2011
[Bone prevention in prostate cancer]T Bessede, N Houede, T Lebret
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 27, 2012
[Intradiverticular bladder tumours: review of the Cancer Committee of the French Association of Urology]Y Neuzillet, E Comperat, M Rouprêt, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 5, 2013
[Surgical treatment of metastatic urothelial carcinoma of the bladder: Review of the Cancer Committee of the French Association of Urology]Y Neuzillet, S Larré, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trialK Fizazi, G Gravis, A Flechon, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 19, 2016
[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]Y Neuzillet, P Colin, E Comperat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 8, 2015
[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)]Y Neuzillet, F Dubosq, E Xylinas, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 7, 2010
[Recommendations Onco-Urology 2010: Urothelial tumors]C Pfister, M Roupret, H Wallerand, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]E Compérat, S Larré, Y Neuzillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)M Roupret, A Bertaut, G Pignot, et al.
Pageof 1